New hope for Hard-to-Treat cancers: LP-184 enters human trials

NCT ID NCT05933265

First seen May 11, 2026 · Last updated May 11, 2026 · Updated 1 time

Summary

This study tests a new drug called LP-184 in people with advanced solid tumors (like certain breast, lung, or pancreatic cancers) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 64 participants will receive LP-184 infusions twice per cycle and be closely monitored for side effects and how the drug works in their body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Highlands Oncology Group

    Springdale, Arkansas, 72758, United States

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • John Hopkins - The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21287, United States

  • Norton Healthcare, Inc.

    Louisville, Kentucky, 40205, United States

  • START Mountain Region

    West Valley City, Utah, 84119, United States

  • UT Health Science Center San Antonio

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.